https://www.selleckchem.com/products/azd-9574.html
ired to identify therapeutic interventions targeting LA myopathy to improve outcomes in HFpEF. The PIONEER-HF (comParIson Of sacubitril/valsartaN versus Enalapril on Effect on nt-pRo-bnp in patients stabilized from an acute HeartFailure episode) trial demonstrated the efficacy and safety of sacubitril/valsartan (S/V) in stabilized patients with acute decompensated heart failure (HF) and reduced ejection fraction. The study sought to determine whether and how prior HF history and treatment with an angiotensin-converting enzyme (ACE) inh
Like
Comment
Share
